Ginevra Doglioni

Ginevra Doglioni

Auto-generated profile, based on publicly available information

Ginevra Doglioni

Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MRMatteo Rossi
Matteo Rossi
PAPatricia Altea-Manzano
Patricia Altea-Manzano
MDMargherita Demicco
Margherita Demicco
GDGinevra Doglioni
Ginevra Doglioni
LBLaura Bornes
Laura Bornes
SFSarah-Maria Fendt
Sarah-Maria Fendt

2 February 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
PAPatricia Altea-Manzano
Patricia Altea-Manzano
GDGinevra Doglioni
Ginevra Doglioni
YLYawen Liu
Yawen Liu
ACAlejandro M. Cuadros
Alejandro M. Cuadros
ENEmma Nolan
Emma Nolan
SFSarah-Maria Fendt
Sarah-Maria Fendt
Metabolic rewiring is often considered an adaptive pressure limiting metastasis formation; however, some nutrients available at distant organs may inherently promote metastatic growth. We find that the lung and liver are lipid-rich environments. Moreover, we observe that pre-metastatic niche formation increases palmitate availability only in the lung, whereas a high-fat diet increases it in both organs. In line with this, targeting palmitate processing inhibits breast cancer-derived lung metastasis formation. Mechanistically, breast cancer cells use palmitate to synthesize acetyl-CoA in a carnitine palmitoyltransferase 1a-dependent manner. Concomitantly, lysine acetyltransferase 2a expression is promoted by palmitate, linking the available acetyl-CoA to the acetylation of the nuclear factor-kappaB subunit p65. Deletion of lysine acetyltransferase 2a or carnitine palmitoyltransferase 1a reduces metastasis formation in lean and high-fat diet mice, and lung and liver metastases from patients with breast cancer show coexpression of both proteins. In conclusion, palmitate-rich environments foster metastases growth by increasing p65 acetylation, resulting in a pro-metastatic nuclear factor-kappaB signaling.

6 June 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
TSTommaso Scolaro
Tommaso Scolaro
MMMarta Manco
Marta Manco
MPMathieu Pecqueux
Mathieu Pecqueux
RARicardo Amorim
Ricardo Amorim
RTRosa Trotta
Rosa Trotta
Massimiliano MazzoneMassimiliano Mazzone
Massimiliano Mazzone
Many individuals with cancer are resistant to immunotherapies. Here, we identify the gene encoding the pyrimidine salvage pathway enzyme cytidine deaminase (CDA) among the top upregulated metabolic genes in several immunotherapy-resistant tumors. We show that CDA in cancer cells contributes to the uridine diphosphate (UDP) pool. Extracellular UDP hijacks immunosuppressive tumor-associated macrophages (TAMs) through its receptor P2Y6. Pharmacologic or genetic inhibition of CDA in cancer cells (or P2Y6 in TAMs) disrupts TAM-mediated immunosuppression, promoting cytotoxic T cell entry and susceptibility to anti-programmed cell death protein 1 (anti-PD-1) treatment in resistant pancreatic ductal adenocarcinoma (PDAC) and melanoma models. Conversely, CDA overexpression in CDA-depleted PDACs or anti-PD-1-responsive colorectal tumors or systemic UDP administration (re)establishes resistance. In individuals with PDAC, high CDA levels in cancer cells correlate with increased TAMs, lower cytotoxic T cells and possibly anti-PD-1 resistance. In a pan-cancer single-cell atlas, CDAhigh cancer cells match with T cell cytotoxicity dysfunction and P2RY6high TAMs. Overall, we suggest CDA and P2Y6 as potential targets for cancer immunotherapy.

1 January 2025 in Nature
Verified
Journal Article
Open access
PDF file
GDGinevra Doglioni
Ginevra Doglioni
JFJuan Fernández-García
Juan Fernández-García
SISebastian Igelmann
Sebastian Igelmann
PAPatricia Altea-Manzano
Patricia Altea-Manzano
ABArnaud Blomme
Arnaud Blomme
SFSarah-Maria Fendt
Sarah-Maria Fendt
Lung metastases occur in up to 54% of patients with metastatic tumours1,2. Contributing factors to this high frequency include the physical properties of the pulmonary system and a less oxidative environment that may favour the survival of cancer cells3. Moreover, secreted factors from primary tumours alter immune cells and the extracellular matrix of the lung, creating a permissive pre-metastatic environment primed for the arriving cancer cells4,5. Nutrients are also primed during pre-metastatic niche formation6. Yet, whether and how nutrients available in organs in which tumours metastasize confer cancer cells with aggressive traits is mostly undefined. Here we found that pulmonary aspartate triggers a cellular signalling cascade in disseminated cancer cells, resulting in a translational programme that boosts aggressiveness of lung metastases. Specifically, we observe that patients and mice with breast cancer have high concentrations of aspartate in their lung interstitial fluid. This extracellular aspartate activates the ionotropic N-methyl-d-aspartate receptor in cancer cells, which promotes CREB-dependent expression of deoxyhypusine hydroxylase (DOHH). DOHH is essential for hypusination, a post-translational modification that is required for the activity of the non-classical translation initiation factor eIF5A. In turn, a translational programme with TGFβ signalling as a central hub promotes collagen synthesis in lung-disseminated breast cancer cells. We detected key proteins of this mechanism in lung metastases from patients with breast cancer. In summary, we found that aspartate, a classical biosynthesis metabolite, functions in the lung environment as an extracellular signalling molecule to promote aggressiveness of metastases.

30 August 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MRMatteo Rossi
Matteo Rossi
PAPatricia Altea-Manzano
Patricia Altea-Manzano
MDMargherita Demicco
Margherita Demicco
GDGinevra Doglioni
Ginevra Doglioni
LBLaura Bornes
Laura Bornes
SFSarah-Maria Fendt
Sarah-Maria Fendt

24 October 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
PAPatricia Altea-Manzano
Patricia Altea-Manzano
GDGinevra Doglioni
Ginevra Doglioni
ACAlejandro M. Cuadros
Alejandro M. Cuadros
ENEmma Nolan
Emma Nolan
JFJuan Fernandez-Garcia
Juan Fernandez-Garcia
SFSarah-Maria Fendt
Sarah-Maria Fendt
Cancer cells outgrowing in distant organs of metastasis rewire their metabolism to fuel on the available nutrients. While this is often considered an adaptive pressure limiting metastasis formation, some nutrients available at the metastatic site naturally or through changes in organ physiology may inherently promote metastatic growth. We find that the lung, a frequent site of metastasis, is a lipid-rich environment. Moreover, we observe that pathological conditions such as pre-metastatic niche formation and obesity further increase the availability of the fatty acid palmitate in the lung. We find that targeting palmitate processing inhibits spheroid growth in vitro and metastasis formation in lean and obese mice. Mechanistically, we discover that breast cancer cells use palmitate to synthesize acetyl-CoA in a carnitine palmitoyltransferase 1a (CPT1a)-dependent manner. Lysine acetyltransferase 2a (KAT2a), whose expression is promoted by palmitate availability, relies on the available acetyl-CoA to acetylate the NF-κB subunit p65. This favors nuclear location of p65 and activates a pro-metastatic transcriptional program. Accordingly, deletion of KAT2a phenocopies CPT1a silencing in vitro as well as in vivo and patients with breast cancer show co-expression of both proteins in metastases across palmitate-rich metastatic sites. In conclusion, we find that palmitate-rich environments foster metastasis growth by increasing p65 acetylation resulting in elevated NF-κB signaling.